Drug Trial Radar · NCT06754852
A Study Assessing HMB-002 in Participants With Von Willebrand Disease
Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
108
Planned (sponsor's estimate)
Start
Feb 6, 2025
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Hemab ApSIndustry
- Sponsor type
- Industry
- First posted
- Jan 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years, up to 69 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human (FIH), Phase 1/2, 3-part open-label, dose escalation, safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and efficacy study evaluating HMB-002 in participants with VWD. Part A of the study involves a single ascending dose (SAD) regimen design to establish safety, tolerability, PK, and PD effect. In Part B of the study, the safety and tolerability of repeat dosing will be established prior to cohort expansion to explore efficacy. Part C will evaluate the safety, PK, and PD of a single concomitant dose of HMB-002 and factor concentrate with Type 3 VWD or Type 1 VWD with low residual VWF and FVIII who use factor concentrate as prophylaxis.
Conditions
- Von Willebrand Disease (VWD)
- Von Willebrand Disease (VWD), Type 1
- Von Willebrand Disease (VWD), Type 2
- Von Willebrand Disease (VWD), Type 3
Interventions
HMB-002 (Part A)Drug
HMB-002 will be administered subcutaneously. Part A will utilize sentinel dosing. The planned duration of study participants in Part A is approximately 12 weeks.
HMB-002 (Part B)Drug
HMB-002 will be administered subcutaneously. Part B dosing intervals will be determined following evaluation of Part A results. The planned duration of study participants in Part B will be approximately 21 weeks.
HMB-002 with Concomitant Factor Concentrate (Part C) (Not Applicable in US)Drug
HMB-002 will be administered as a single dose with a concomitant single dose of factor concentrate. The planned duration of study participants in Part C will be approximately 17 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment emergent adverse events (TEAE)Time frame: up to Day 113
Locations
25 sites in 3 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona · Not yet recruiting
Arkansas Children's Hospital
Little Rock, Arkansas · Not yet recruiting
Children's Hospital of Los Angeles
Los Angeles, California · Not yet recruiting
University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center
Miami, Florida · Not yet recruiting
Emory Children's Center
Atlanta, Georgia · Not yet recruiting
Innovative Hematology, Inc./Indiana Hemophilia and Thrombosis Center
Indianapolis, Indiana · Recruiting
Tulane University School of Medicine
New Orleans, Louisiana · Not yet recruiting
University of Michigan Hospitals, Department of Hemophilia and Coagulation Disorders
Ann Arbor, Michigan · Not yet recruiting
Mayo Clinic - Rochester
Rochester, Minnesota · Not yet recruiting
Oregon Health & Science University
Portland, Oregon · Not yet recruiting
Hemophilia Center of Western Pennsylvania
Pittsburgh, Pennsylvania · Not yet recruiting
The University of Texas Southwestern Medical Center
Dallas, Texas · Not yet recruiting
Washington Institute For Coagulation (WIC)
Seattle, Washington · Not yet recruiting
Fiona Stanley Hospital
Murdoch, Perth, Australia · Not yet recruiting
Royal Prince Alfred Hospital
Camperdown, Sydney, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom · Not yet recruiting
University Hospital of Wales
Cardiff, United Kingdom · Recruiting
St James's University Hospital, Leeds Haemophilia Centre
Leeds, United Kingdom · Not yet recruiting
Royal Liverpool and Broadgreen University Hospitals NHS TRUST, The Roald Dahl Haemostasis and Thrombosis Centre
Liverpool, United Kingdom · Not yet recruiting
Richmond Pharmacology
London, United Kingdom · Recruiting
St Thomas' Hospital
London, United Kingdom · Not yet recruiting
Basingstoke and North Hampshire Hospital
Basingstoke, Hampshire, United Kingdom · Recruiting
St George's Hospital
Tooting, London, United Kingdom · Not yet recruiting
Royal London Hospital
Whitechapel, London, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.